(Q37606292)

21 August 2017

1 reference

title

Predicting responders to therapies for multiple sclerosis (English)

1 reference

21 August 2017

0 references

Jordi Río

1

1 reference

21 August 2017

Manuel Comabella

series ordinal

2

1 reference

21 August 2017

Xavier Montalban

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

21 August 2017

Nature Reviews Neurology

1 reference

21 August 2017

5

1 reference

21 August 2017

10

1 reference

21 August 2017

553-560

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2009.139

21 August 2017

0 references

cites work

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Clinical characteristics of responders to interferon therapy for relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Transcription-based prediction of response to IFNbeta using supervised computational methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Interferon beta in relapsing–remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

A prospective study on the prognosis of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

The natural history of multiple sclerosis: a regional study with some longitudinal data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Predicting beta-interferon failure in relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Regression to the mean in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Prognosis in initial stage of disseminated primary demyelinating disease of central nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Guidelines for MRI monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society's task force

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Clinical characteristics of responders to interferon therapy for relapsing MS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Defining interferon beta response status in multiple sclerosis patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

A composite score to predict short-term disease activity in patients with relapsing-remitting MS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Measures in the first year of therapy predict the response to interferon β in MS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Science, medicine, and the future: Pharmacogenetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Genomics in multiple sclerosis--current state and future directions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

HLA class II and response to interferon-beta in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.139

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

31 March 2020

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis

1 reference

12 December 2020

The course of multiple sclerosis in 73 cases with computer-designed curves

1 reference

12 December 2020

The frequency of relapse in multiple sclerosis. A study based on 245 cases

1 reference

12 December 2020

Treatment optimization in multiple sclerosis

1 reference

12 December 2020

10.1038/NRNEUROL.2009.139

Identifiers

DOI

1 reference

Dimensions Publication ID

21 August 2017

0 references

1 reference